Full Text

• [1] Newton, K., Dixit, V.M., Signaling in innate immunity and inflammation. Cold Spring Harb. Perspect. Biol., 4, 2012, a006049.
• [2] Overington, J.P., Al-Lazikani, B., Hopkins, A.L., How many drug targets are there?. Nat. Rev. Drug Discov. 5 (2006), 993–996.
• [3] Stevens, R.C., Cherezov, V., Katritch, V., Abagyan, R., Kuhn, P., Rosen, H., Wüthrich, K., The GPCR Network: a large-scale collaboration to determine human GPCR structure and function. Nat. Rev. Drug Discov. 12 (2013), 25–34.
• [4] Kenakin, T., Theoretical aspects of GPCR–ligand complex pharmacology. Chem. Rev., 2016, 10.1021/acs.chemrev.5b00561.
• [5] Wettschureck, N., Offermanns, S., Mammalian G proteins and their cell type specific functions. Physiol. Rev. 85 (2005), 1159–1204.
• [6] DeWire, S.M., Ahn, S., Lefkowitz, R.J., Shenoy, S.K., Beta-arrestins and cell signaling. Annu. Rev. Physiol. 69 (2007), 483–510.
• [7] Smith, J.S., Rajagopal, S., The β-arrestins: multifunctional regulators of G protein-coupled receptors. J. Biol. Chem. 291 (2016), 8969–8977.
• [8] Lefkowitz, R.J., Shenoy, S.K., Transduction of receptor signals by beta-arrestins. Science 308 (2005), 512–517.
• [9] Irannejad, R., von Zastrow, M., GPCR signaling along the endocytic pathway. Curr. Opin. Cell Biol. 27 (2014), 109–116.
• [10] Alvarez-Curto, E., Milligan, G., Metabolism meets immunity: the role of free fatty acid receptors in the immune system. Biochem. Pharmacol. 114 (2016), 3–13.
• [11] Szpakowska, M., Dupuis, N., Baragli, A., Counson, M., Hanson, J., Piette, J., et al. Human herpesvirus 8-encoded chemokine vCCL2/vMIP-II is an agonist of the atypical chemokine receptor ACKR3/CXCR7. Biochem. Pharmacol. 114 (2016), 14–21.
• [12] Dahlgren, C., Gabl, M., Holdfeldt, A., Winther, M., Forsman, H., Basic characteristics of the neutrophil receptors that recognize formylated peptides, a danger-associated molecular pattern generated by bacteria and mitochondria. Biochem. Pharmacol. 114 (2016), 22–39.
• [13] Kehrl, J.H., The impact of RGS and other G-protein regulatory proteins on Gαi-mediated signaling in immunity. Biochem. Pharmacol. 114 (2016), 40–52.
• [14] Kenakin, T.P., Functional selectivity and biased receptor signaling. J. Pharmacol. Exp. Ther. 336 (2011), 296–302.
• [15] Shukla, S.K., Singh, G., Ghosh, E., Emerging structural insights into biased GPCR signaling. Trends Biochem. Sci. 39 (2014), 594–602.
• [16] Kleist, A.B., Getschman, A.E., Ziarek, J.J., Nevins, A.M., Gauthier, P.A., Chevigné, A., et al. New paradigms in chemokine receptor signal transduction: moving beyond the two-site model. Biochem. Pharmacol. 114 (2016), 53–68.
• [17] Zhang, J., Feng, H., Xu, S., Feng, P., Hijacking GPCRs by viral pathogens and tumor. Biochem. Pharmacol. 114 (2016), 69–81.
• [18] Szpakowska, M., Chevigné, A., VCCL2/vMIP-II, the viral master KEYmokine. J. Leukoc. Biol. 99 (2016), 893–900.
• [19] Reboul, J., Ewbank, J.J., GPCRs in invertebrate innate immunity. Biochem. Pharmacol. 114 (2016), 82–87.
• [20] Alexander, S.P.H., Davenport, A.P., Kelly, E., Marrion, N., Peters, J.A., Benson, H.E., et al. The concise guide to pharmacology 2015/16: G protein-coupled receptors. Br. J. Pharmacol. 172 (2015), 5744–5869.
• [21] Roth, B.L., Kroeze, W.K., Integrated approaches for genome-wide interrogation of the druggable non-olfactory G protein-coupled receptor superfamily. J. Biol. Chem. 290 (2015), 19471–19477.
• [22] Nijmeijer, S., Vischer, H.F., Leurs, R., Adhesion GPCRs in immunology. Biochem. Pharmacol. 114 (2016), 88–102.
• [23] Liu, R., Wong, W., IJzerman, A.P., Human G protein-coupled receptor studies in Saccharomyces cerevisiae. Biochem. Pharmacol. 114 (2016), 103–115.